China Biopsy Devices Market Set for Steady Growth as Cancer Diagnostics Advance

Introduction

China’s healthcare sector is undergoing rapid transformation, and the demand for advanced diagnostic technologies is rising alongside it. Among the most critical tools in modern diagnostics are biopsy devices—specialized instruments designed to collect tissue samples for laboratory analysis. These devices play a vital role in detecting diseases such as cancer, infections, and inflammatory conditions.

According to recent industry analysis by Renub Research, the China biopsy devices market is projected to grow significantly in the coming years. The market is expected to expand from US$ 612.62 million in 2024 to approximately US$ 1,131.98 million by 2033, registering a compound annual growth rate (CAGR) of 7.06% between 2025 and 2033.

Download Sample Report

Several factors are contributing to this growth trajectory. The rising prevalence of cancer, the increasing demand for minimally invasive procedures, technological innovation in diagnostic equipment, and expanding healthcare infrastructure across China are all driving the adoption of biopsy devices.

As healthcare providers seek faster, more accurate diagnostic methods, biopsy technologies are becoming an essential component of modern medical care throughout the country.

Understanding Biopsy Devices and Their Role in Modern Medicine

Biopsy devices are medical tools used to extract small samples of tissue from the human body. These samples are then analyzed in laboratories to identify abnormalities such as cancer cells, infections, or other pathological conditions.

The devices come in multiple forms, including:

Needle-based biopsy guns

Vacuum-assisted biopsy systems

Biopsy forceps

Image-guided biopsy devices

These technologies allow physicians to obtain tissue samples with high precision while minimizing discomfort and recovery time for patients.

Biopsies are commonly performed on organs such as the breast, lungs, liver, prostate, and gastrointestinal tract, making them indispensable for cancer detection and disease monitoring.

In China, the increasing emphasis on early disease detection and precision medicine has greatly expanded the role of biopsy procedures. Hospitals and diagnostic centers are adopting advanced imaging-guided biopsy systems to improve diagnostic accuracy and patient outcomes.

Rising Cancer Prevalence Driving Diagnostic Demand

One of the most important drivers of the biopsy devices market in China is the increasing burden of cancer.

Lifestyle changes, aging populations, environmental pollution, and dietary habits have all contributed to a growing number of cancer diagnoses. Early detection is essential for improving survival rates, and biopsy procedures are central to confirming cancer diagnoses.

In 2022, China recorded approximately:

4,824,700 new cancer cases

2,574,200 cancer-related deaths

The most commonly diagnosed cancers include:

Lung cancer

Colorectal cancer

Thyroid cancer

Liver cancer

Stomach cancer

Together, these cancers accounted for over 57% of new cases in the country.

With cancer cases rising, healthcare providers are increasingly relying on biopsy procedures to confirm diagnoses, determine disease stages, and guide treatment decisions. This rising clinical demand is directly supporting the growth of biopsy device adoption across hospitals and specialized diagnostic centers.

Technological Advancements Transforming Biopsy Procedures

Technological innovation is reshaping the biopsy landscape in China. Modern biopsy systems now incorporate advanced imaging technologies that enable physicians to collect tissue samples with greater accuracy and safety.

Some of the most significant technological improvements include:

Ultrasound-guided biopsy systems for real-time imaging

CT-guided biopsy devices for deep tissue sampling

MRI-guided biopsy tools for highly detailed imaging

Robotic-assisted biopsy technologies for enhanced precision

These technologies allow clinicians to target suspicious tissue more accurately while reducing patient discomfort and procedure time.

In March 2024, a major development occurred when Intuitive Surgical received regulatory approval in China to sell its Ion surgical robotic system, highlighting the country’s openness to adopting advanced medical technologies.

Minimally invasive biopsy techniques are becoming increasingly popular because they offer several benefits:

Reduced surgical risks

Shorter recovery periods

Lower hospitalization rates

Improved patient comfort

As hospitals seek more efficient diagnostic procedures, these innovations are accelerating the demand for sophisticated biopsy devices.

Expanding Healthcare Infrastructure Supporting Market Growth

China has been investing heavily in healthcare infrastructure, and this expansion is playing a key role in the growth of the biopsy devices market.

The government has prioritized improving access to medical services by building new hospitals, diagnostic centers, and cancer treatment facilities across the country. These investments are enabling advanced diagnostic technologies to reach not only large metropolitan areas but also smaller cities and rural communities.

A significant policy shift occurred in September 2024, when China’s Ministry of Commerce and health authorities announced new regulations allowing foreign-owned hospitals in major cities such as Beijing and Shanghai. The government also relaxed restrictions on foreign investment in healthcare institutions.

This policy change is expected to bring international expertise, advanced equipment, and innovative technologies into China’s healthcare system, further strengthening the adoption of modern diagnostic tools including biopsy devices.

As healthcare infrastructure continues to expand, the availability of diagnostic technologies is likely to improve, supporting long-term market growth.

Key Challenges Facing the Biopsy Devices Market

Despite strong growth potential, several challenges still affect the widespread adoption of biopsy technologies in China.

High Cost of Advanced Biopsy Devices

One of the primary barriers to adoption is the high cost associated with advanced biopsy systems. Technologies such as robotic-assisted or MRI-guided biopsy devices require significant investment in equipment, maintenance, and training.

Many healthcare institutions—especially those in less developed regions—face financial constraints that limit their ability to purchase these sophisticated systems.

As a result, access to advanced biopsy technologies remains uneven across the country.

Shortage of Skilled Medical Professionals

Another challenge is the shortage of highly trained professionals capable of operating advanced biopsy equipment and interpreting diagnostic results.

Operating modern imaging-guided biopsy systems requires specialized training and technical expertise. However, many rural or smaller healthcare facilities lack access to trained specialists.

This shortage can reduce the effectiveness of biopsy technologies and slow their adoption in certain areas.

Addressing this skills gap through medical education and professional training programs will be critical for the future growth of the biopsy devices market.

Growth in Needle-Based Biopsy Devices

Among the various product categories, needle-based biopsy guns are gaining significant popularity in China.

These devices allow physicians to collect tissue samples quickly and accurately while minimizing patient discomfort. They are widely used in diagnosing cancers affecting organs such as:

Liver

Breast

Lungs

Prostate

Needle-based biopsy procedures are minimally invasive and can often be performed in outpatient settings, making them highly efficient and cost-effective.

With increasing awareness about early cancer detection, hospitals and diagnostic centers are expanding their use of these devices, driving strong demand within this product segment.

Rising Demand for Breast Biopsy Devices

The breast biopsy devices market in China is also expanding rapidly due to growing awareness of breast cancer and the importance of early diagnosis.

Healthcare providers are increasingly using advanced technologies such as:

Vacuum-assisted biopsy systems

Core needle biopsy devices

Image-guided diagnostic tools

These technologies enable physicians to detect breast cancer at earlier stages and provide more accurate diagnoses.

In February 2024, Hologic introduced its Selenia Dimensions 3D Mammography System, which enhances breast cancer detection through improved imaging and precise biopsy guidance.

As public awareness campaigns and screening programs expand, demand for breast biopsy technologies is expected to continue rising.

Lung Biopsy Devices Market Expansion

Lung cancer remains one of the leading causes of cancer-related deaths in China. Factors such as air pollution and high smoking rates contribute to the large number of lung cancer cases diagnosed each year.

Accurate and timely diagnosis is critical for effective treatment, and lung biopsies play a central role in confirming the disease.

Advanced imaging-guided biopsy techniques—particularly CT-guided biopsy systems—are widely used for detecting lung tumors and collecting tissue samples from deep lung tissues.

These technologies significantly improve diagnostic precision, allowing physicians to identify cancer earlier and develop targeted treatment plans.

As lung cancer cases continue to rise, demand for specialized lung biopsy devices is expected to increase steadily.

Growth in CT Scan–Guided Biopsy Devices

CT-guided biopsy systems are becoming increasingly popular in China due to their ability to detect and target deep-seated lesions with high precision.

These systems combine advanced imaging with biopsy technology, enabling physicians to perform procedures safely and accurately.

CT-guided biopsies are widely used for diagnosing conditions in organs such as:

Lungs

Liver

Bones

Abdomen

The ability to visualize internal structures in detail makes CT-guided biopsy one of the most reliable diagnostic techniques available today.

As imaging technology continues to improve, CT-guided biopsy devices are expected to remain a major contributor to market growth.

Emerging Role of MRI-Guided Biopsy Devices

MRI-guided biopsy devices are also gaining attention in China due to their superior imaging capabilities.

Magnetic resonance imaging provides highly detailed images of soft tissues, making it especially useful for diagnosing complex conditions in areas such as the brain and breast.

MRI-guided biopsy procedures allow physicians to target suspicious tissues with exceptional accuracy, improving diagnostic confidence and treatment planning.

Although these systems are more expensive than other imaging technologies, their growing adoption reflects the increasing demand for precision medicine and advanced diagnostics.

Importance of Diagnostic and Imaging Centers

Diagnostic and imaging centers play a critical role in the growth of the biopsy devices market in China.

These facilities specialize in advanced imaging services and are often equipped with state-of-the-art diagnostic technologies. Their expertise enables them to provide accurate and timely diagnoses for a wide range of medical conditions.

As healthcare demand increases, diagnostic centers are expanding their capabilities by incorporating advanced biopsy technologies.

This trend is helping improve healthcare accessibility and enabling earlier disease detection across the country.

Market Segmentation

The China biopsy devices market can be segmented across several key categories.

By Product

Needle-Based Guns

Biopsy Guidance Systems

Biopsy Needles

Biopsy Forceps

Others

By Application

Breast Biopsy

Lung Biopsy

Prostate Biopsy

Liver Biopsy

Gastroenterology Biopsy

Others

By Technology

CT Scan Guided

Stereotactic Guided

Ultrasound Guided

MRI Guided

Others

By End User

Hospitals

Diagnostic & Imaging Centers

Others

Competitive Landscape

Several major medical device companies are active in China’s biopsy devices market, contributing to technological innovation and market expansion.

Key companies include:

Cardinal Health, Inc.

Hologic, Inc.

Danaher Corporation

Becton, Dickinson and Company

Boston Scientific Corporation

Medtronic plc

Olympus Corporation

CONMED Corporation

These companies are focusing on product development, strategic partnerships, and regulatory approvals to strengthen their presence in China’s rapidly growing healthcare sector.

Final Thoughts

China’s biopsy devices market is entering a period of steady expansion as the country continues to strengthen its healthcare infrastructure and prioritize early disease detection.

The rising burden of cancer, combined with advances in imaging technology and minimally invasive diagnostics, is driving demand for innovative biopsy solutions. Government initiatives and healthcare investments are further supporting the adoption of modern diagnostic tools.

With the market expected to reach US$ 1,131.98 million by 2033, the role of biopsy technologies in China’s healthcare system will only become more significant in the years ahead.

As hospitals, diagnostic centers, and medical technology companies continue to innovate, biopsy devices will remain at the forefront of modern diagnostics—helping physicians detect diseases earlier, treat patients more effectively, and ultimately improve healthcare outcomes across China.